An expert team of researchers and clinicians in microbiology, virology, pathology, molecular science, and immunology at the Icahn School of Medicine at Mount Sinai (ISMMS) and The Mount Sinai Hospital (MSH) have been working together around the clock to design, validate, and implement an “end-to-end” clinical pathology laboratory solution that will allow for the testing of approximately several hundred people per day in order to rapidly diagnose and help guide the selection of treatment and monitor disease course.
Using a high-throughput, automated molecular assay, The Mount Sinai Hospital Clinical Laboratories are currently testing several hundred patients per day for SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19) to identify positive versus negative cases. The testing effort will ramp up to a capacity of 1,000 tests per day. Mount Sinai follows NY State guidelines and is only testing patients with trouble breathing and/or moderate-to-severe respiratory symptoms at this time. (Please consult your physician if you believe you are a candidate for testing.)
For patients who test positive for SARS-CoV-2, a quantitative assay designed and implemented by a multidisciplinary Mount Sinai team is capable of measuring whether the patient’s viral load is high or low. The viral load findings will be studied to ascertain whether they assist in managing the disease and aiding in the selection of effective treatments. The clinical laboratory efforts are being led by Peter Palese, MD, Horace W. Goldsmith Professor and Chair of Microbiology, and Carlos Cordon-Cardo, MD, PhD, Irene Heinz Given and John LaPorte Given Professor and Chair of Pathology, Molecular and Cell-Based Medicine.tion:
A team at New York's Icahn School of Medicine at Mount Sinai (NY, USA), has published details of antibody tests that use either the whole spike protein, modified slightly to improve its stability during mass production in cell lines, or only the receptor-binding domain.
Mount Sinai Health System and Harbour BioMed have signed a multi-year collaboration to develop antibodies for the treatment of various diseases. The partners will also utilise the H2L2 Harbour Mice® platform to develop antibodies against the SARS-CoV-2.